Oxford’s Eden Research gets go-ahead for biofungicide in Poland

Oxford-based sustainable biopesticide firm Eden Research has announced that its flagship biofungicide, Mevalone, has obtained regulatory authorisation in Poland.

This will mean farmers in Poland can apply the product to wine and table grapes to protect and treat outbreaks of Botrytris cinerea and to apples to prevent post-harvest storage diseases.

SumiAgro Europe has been appointed as the exclusive distributor of Mevalone in the territory with product distribution expected to commence imminently. SumiAgro has extensive experience with the fungicide, having previously supported Eden with significant label extensions in France.

As the EU’s largest producer of apples, Poland represents a significant market for Eden Research and Mevalone. Eden expects to receive additional regulatory approvals in due course in additional Central European member states such as Germany, Austria, and Hungary, where high levels of wine production are found.

Read more - Eden Research authorised to use flagship biofungicide for home and garden use

Eden CEO Sean Smith said: “Our regulatory approval in Poland marks the beginning of our commercial push into Central Europe, and we are excited by further approvals in the region in due course.

“While the Polish grape market is relatively small when compared with neighbouring Central European countries, we are encouraged by the opportunities that lie within the apples segment for post-harvest storage disease control.

“Pre-harvest application of Mevalone helps to protect produce from diseases that can develop during the long storage period, further demonstrating the versatility within our product offering.

“We are proud to be able to provide farmers with a highly effective crop protection solution that not only supports sustainability in agriculture but also helps to reduce food waste in the supply chain.

“Furthermore, we are delighted to continue our partnership with SumiAgro, a company with significant influence across Central Europe and the ability to gain market share. We expect distribution of our product to commence imminently with meaningful sales to be realised in the upcoming seasons.”

Read more - Oxford Innovation invests in OSSTEC’s bone healing implants